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VIII. Abstract and keywords  
 
ABSTRACT 
Background and Purpose: 
L-DOPA-induced dyskinesia (LID) remains a major complication of L-DOPA therapy in 
Parkinson's disease. LID is believed to result from inhibition of substantia nigra reticulata 
(SNr) neurons by GABAergic striatal projection neurons that become supersensitive to  
dopamine receptor stimulation after severe nigrostriatal degeneration. Here we asked if 
stimulation of direct medium spiny neuron (dMSN) GABAergic terminals at the SNr can 
produce a full dyskinetic state similar to that induced by L-DOPA. 
 
Experimental Approach:  
Adult C57BL6 mice were lesioned with 6-hydroxydopamine (6-OHDA) in the medial 
forebrain bundle. Channelrhodopsin was expressed in striatonigral terminals by ipsilateral 
striatal injection of adeno-associated viral particles under the CaMKII promoter. Optic fibres 
were implanted on the ipsilateral SNr. Optical stimulation was performed before and 24 h 
after three daily doses of L-DOPA at subthreshold and suprathreshold dyskinetic doses. We 
also examined the combined effect of light stimulation and an acute L-DOPA challenge.  
 
Key Results: 
Optostimulation of striatonigral terminals inhibited SNr neurons and induced all dyskinesia 
subtypes (optostimulation- induced dyskinesia; OID) in 6-OHDA animals, but not in sham-
lesioned animals. Additionally, chronic L-DOPA administration sensitized the dyskinetic 
response to striatonigral terminal optostimulation, as OIDs were more severe 24 h after L-
DOPA administration. Furthermore, L-DOPA combined with light stimulation did not result 
in higher dyskinesia scores than OID alone, suggesting that optostimulation has a masking 
effect on LID. 
 
 
This article is protected by copyright. All rights reserved. 
 
Conclusion and Implications: 
This work suggests that striatonigral inhibition of basal ganglia output (SNr) is a decisive 
mechanism mediating LID and identifies the SNr as a target for managing LID.   
 
 
Keywords: Dyskinesia, L-DOPA, Substantia nigra, D1 receptor, medium spiny neurons, 
optogenetics. 
Abbreviations: 6-OHDA, 6-Hydroxydopamine; AAV, adeno-associated virus; ChR2, 
channel rhodopsin; D2R, D2 receptor; DA, dopamine; dMSN, direct pathway medium spiny 
neuron; eYFP, enhanced yellow fluorescent protein; GPi, internal globus pallidus; iMSN, 
indirect pathway medium spiny neuron; LID, L-DOPA induced dyskinesia; MPTP, 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine; OID, optogenetically induced dyskinesia; PD, 
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INTRODUCTION  
L-DOPA-induced dyskinesia (LID) remains a major complication of chronic L-DOPA 
therapy in Parkinson's disease (PD). LID arises after chronic pulsatile stimulation of striatal 
dopamine (DA) receptors in patients who, due to severe nigrostriatal terminal degeneration, 
have lost their capacity to buffer fluctuations of extracellular DA (Cenci et al., 2010; Jenner, 
2008; Murer & Moratalla, 2011). However, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)- intoxicated patients who quickly develop severe PD symptoms show LID shortly 
after beginning treatment (Ballard et al., 1985) and similarly a first challenge with L-DOPA 
induces dyskinesia in severely DA-depleted animals. Furthermore, optogenetic or 
chemogenetic stimulation of severely dopamine denervated striatal neurons in L-DOPA-
naïve rodents can induce dyskinesia resembling LID (Alcacer et al., 2017; F. Hernández et 
al., 2017; Perez et al., 2017). Altogether this work suggests that loss of DA input can modify 
striatal circuit function such that striatal activation induces dyskinesia instead of normal 
actions (Picconi & Calabresi, 2017).  
During dyskinesia induced by dopamine receptor stimulation in patients and animal 
models of PD, neurons at the internal pallidal segment (GPi) and substantia nigra pars 
reticulata (SNr) are markedly inhibited (Aristieta et al., 2016; Boraud et al., 2001; Filion et 
al., 1991; Lozano et al., 2000; Meissner et al., 2006; Papa et al., 1999). The main source of 
SNr inhibition is GABA released by striatal medium spiny neurons of the direct pathway 
(dMSNs) (Freeze et al., 2013). These neurons express the dopamine D1 receptor (D1R), 
which is crucial and necessary for the development of LID (Darmopil et al., 2009; Murer & 
Moratalla, 2011; Halje et al., 2012). Whether the indirect pathway contributes to LID is still 
controversial. Agonists of D2 receptor (D2R), expressed in the indirect pathway medium 
spiny neurons (iMSN), only induce dyskinesia in animals that have been primed with mixed 
D1/D2 agonists (Delfino et al., 2004; Luquin et al., 1992) and do not substantially modify 
LID in patients (Rascol et al., 2006). Interestingly, LID is not modified by inactivation of 
D2R (Darmopil et al., 2009), but is reduced by chemogenetic activation of iMSNs (Alcacer et 
al., 2017). Importantly, in previous studies, stimulation of dMSNs produced dyskinesia that 
was less intense and varied than that observed with L-DOPA, except when chemogenetic 
activation of dMSNs was combined with D2 agonist administration. This suggests that D2R 
inhibition of iMSNs is necessary for full expression of LID (Alcacer et al., 2017) as predicted 
by classical models and suggest that an activity imbalance between dMSNs and iMSNs 
drives LID (DeLong, 1990; Jenner, 2008; Suarez et al, 2014, 2016, 2018). However, recent 
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studies challenge classical views: dMSNs and iMSNs are coactivated during movement (Cui 
et al., 2013, Parker et al., 2018, (Ryan et al., 2018) and optogenetic co-stimulation of dMSNs 
and iMSNs induces dyskinesia in PD rats (F. Hernández et al., 2017). Thus, whether selective 
dMSN stimulation can induce a full repertoire of dyskinetic movements, comparable in 
intensity to those induced by L-DOPA, remains uncertain. 
Here, we asked if optogenetically targeting the densely-packed dMSN terminals at the 
SNr rather than the broadly distributed dMSN cell bodies at the striatum would generate 
dyskinetic movements as intense and varied as those produced with L-DOPA. We also asked 
if dyskinesia-related molecular markers associated with MSN stimulation are expressed 




This study was carried out on adult C57BL/6N mice (RRID:MGI:5825016) from  
 Harlan Iberica, Barcelona, Spain. Animals were housed under a 12-hour light/dark cycle 
with free access to food and water. All experimental procedures conformed to European 
Community guidelines (2003/65/CE) and were approved by the Cajal Institute’s Bioethics 
Committee (following DC86/609/EU). Electrophysiological experiments performed in 
Argentina were also carried out in C57BL/6 mice (RRID:IMSR_CRL:475) from the National 
Academy of Medicine, Buenos Aires, Argentina, following protocols approved by the 
University of Buenos Aires School of Medicine Institutional Animal Care and Use 
Committee. Every effort was made to minimise animal discomfort and the overall number of 
animals used.  
 
Surgical procedures 
All surgeries were conducted under deep surgical anaesthesia (1% isoflurane). Animals were 
mounted on a stereotaxic frame (Kopf Instruments,Tujunga, USA) with a mouse adaptor. 6-
Hydroxydopamine (6-OHDA) injection and viral infection were performed during the same 
surgery. Fibre optic cannulae were implanted in a second surgery 4-6 weeks later.  
 
6-Hydroxydopamine lesion 
6-OHDA hydrobromide with added ascorbic acid was dissolved in saline reaching a fina l 
concentration of 5.75 g/l 6-OHDA in 0.02% ascorbic acid. Mice received 0.7 l injections 
of 6-OHDA or vehicle solution into the left medial forebrain bundle at the following 
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coordinates from bregma (mm): anterior-posterior = -1, medial- lateral = +1.2, dorso-ventral = 
-4.8. Injections were performed at 0.5 l/min using a 300 m-diameter cannula attached to a 
1l Hamilton syringe controlled by a motorised pump (Harvard Apparatus, USA). Special 
care was required after 6-OHDA lesion to ensure survival. Each mouse was weighed daily 
and received a subcutaneous injection of saline and an enriched diet. This procedure 
continued until animals began to regain weight (14-20 days after surgery).    
 
Vector injection 
Immediately after 6-OHDA or vehicle infusion, an adeno-associated virus (AAV) vector 
expressing channelrhodopsin 2 (ChR2) tagged with enhanced yellow fluorescent protein 
(eYFP) and under the CaMKII promoter (AAV-CaMKIIa-hChR2(H134R)-eYFP) was 
injected into the left dorsolateral striatum. Viral concentration was 2.46 x 1013 viral particles 
per ml. 0.5 µl AAV was infused in the left striatum at 0.1 l/min at the following coordinates 
(mm): anterior-posterior= +0.5, medial- lateral= +2.5 and dorso-ventral= -3. An additional 
group of 6-OHDA animals was injected with an AAV vector expressing only eYFP (AAV-
CaMKIIa-eYFP).  
 
Fibre optic cannula implant 
Four to six weeks after 6-OHDA lesion and viral infection, mice were implanted ipsilaterally 
with a fibre optic cannula over the substantia nigra pars reticulata (SNr). We used the 
following coordinates (mm): anterior-posterior = -2.9, medial- lateral = +1.4 and dorso-ventral 
= -4.25. Fibre optic cannulae had a 200m core fibre, flat cleave and 0.22 NA (Doric Lenses, 
Quebec, Canada).  
 
Behavioural tests 
Three weeks after 6-OHDA injection, behavioural testing was performed on 3 non-
consecutive days during the light phase in order to select only severely lesioned animals. All 
mazes and apparatus were thoroughly cleaned with 10% ethanol and dried between subjects.  
 
Actimeter 
General horizontal and vertical exploratory activity in a novel open field was recorded as in 
Ruiz-DeDiego et al. (2018) using a multi-cage activity meter (Columbus Instruments, Ohio, 
USA) with 8 individual cages measuring 20 x 20 x 28 cm. Horizontal movement was 
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detected by 2 arrays of 16 infrared beams, with a third array positioned 4 cm above the floor 
to detect vertical movement. Test sessions lasted 20 min.   
 
Cylinder test 
Each mouse was placed in a 10 cm diameter glass cylinder and videotaped for 3 min. Mice 
responded to the novel environment by standing on their hindlimbs and leaning on the walls 
of the cylinder with their forelimbs. The number of supporting ipsilateral, contralateral and 
simultaneous forepaw placements against the cylinder wall was assessed. Data are expressed 
as a percentage of contralateral forelimb use (% contralateral forelimb use = (contralateral 
contacts / (ipsilateral + contralateral + simultaneous contacts / 2) X 100).  
 
Accelerating rotarod test 
Mice were tested in sets of five, using an accelerating rotarod (from 4 to 40 rpm in 5 min; 
Ugo Basile, Rome, Italy). The latency to fall from the rod was automatically recorded and 
cut-off time was 5 min as in García-Montes et al.(2018). Each animal was assessed in a single 
day over 6 trials with 15 min inter-trial intervals.  
 
Optical stimulation 
Striatonigral terminals were activated using a 473 nm DPSS blue laser (Shanghai Laser, 
Shanghai, China) with a maximum output power of 100 mW. The laser was controlled by an 
Optogenetics TTL Pulse Generator (OPTG) (Doric Lenses, Quebec, Canada) and its power 
was adjusted to be 10 mW at the fibre tip (measured with a PM100D optical power meter 
with an S120C sensor; Thorlabs Inc, Newton, USA). Two optical stimulation protocols were 
used in this study. One consisted of a single 15 s pulse, a 3 min pause, and a second single 
15s pulse tested at 1-10 mW. The second stimulation protocol consisted of a 30 s burst of 
pulsed light at 20 Hz with a 5 or 20 ms pulse duration at 10 mW, a 3 min pause and a second 
30 s burst of light identical to the first. Only one protocol was tested per session and sessions 
were separated by at least 72 h. After eliciting dyskinesias with the two light stimulation 
protocols, animals were subjected to a L-DOPA sensitisation protocol using escalating doses 
of L-DOPA. L-DOPA methyl ester was injected intraperitoneally once per day, 20 min after 
an intraperitoneal benserazide hydrochloride injection. L-DOPA and benserazide doses were 
respectively 2 mg/kg and 6 mg/kg; 3 mg/kg and 6 mg/kg; 6 mg/kg and 6 mg/kg; 9 mg/kg and 
12 mg/kg; 20 mg/kg and 12 mg/kg. Animals were light stimulated twice over one week. In 
the first session, abnormal involuntary movements elicited by laser stimulation were assessed 
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24 h after three daily doses of L-DOPA. The second session took place 72 h later; the 
simultaneous effect of light stimulation combined with an acute dose of L-DOPA was 
assessed. For a graphical explanation of the escalating L-DOPA treatment protocol, please 
see Figures 4A and 6A.   
 
Dyskinesia ratings 
Dyskinesia was rated by two separate raters, one of whom was blind to treatment (sham or 
lesion), based on video footage. Lineal regression analysis on raters’ scores produced an 
R2=0.84. Therefore, the raters’ scores were averaged. Each subtype of dyskinesia (oral, axial, 
forelimb) was scored, considering dyskinesia frequency and amplitude, as described in (Perez 
et al., 2017). Briefly, the frequency scale ranged from 0 to 4 (where 0 = no dyskinesia; 1 = 
occasional dyskinesia displayed for <50% of the observation time; 2 = sustained dyskinesia 
displayed for >50% of the observation time; 3 = continuous dyskinesia; 4 = continuous 
dyskinesia not interruptible by external stimuli). Amplitude scores were subdivided as “A,” 
which indicates oral dyskinesia without tongue protrusion, forelimb dyskinesia without 
shoulder engagement and axial dyskinesia with body twisting <60°, or “B,” indicating oral 
dyskinesia with tongue protrusion, forelimb dyskinesia with shoulder engagement, or axial 
dyskinesia with body twisting ≥60°. Overall scores for the frequency and amplitude of 
dyskinesia used for data analysis were calculated as 1A=1, 1B=2, 2A=2, 2B=4, 3A=4, 3B=6, 
4A=6, 4B=8. This entails that scores for any one component (axial, oral, or forelimb) may be 
rated from 0 to 8. Total dyskinesia scores were calculated as the sum of all components, with 
a total possible maximum score of 24 per rating point.  
 
Tissue preparation 
After behavioural testing, animals were illuminated for one final session with the 20Hz 20ms 
10mW protocol and perfused 50 minutes later. Mice were anaesthetised (sodium 
pentobarbital, 100 mg/kg) and perfused transcardially with cold saline containing heparin 
(500 IU/L) followed by 4% paraformaldehyde (PFA) in phosphate buffer (PB). Brains were 
then dissected, incubated overnight in PFA and then stored in PB. Fixed brains were cut into 
30 µm coronal sections in a vibratome (Leica Microsystems, Wetzlar, Germany) and slices 
were stored free-floating in 0.1M PB containing 0.1% sodium azide at 4°C until use. 6-
OHDA-induced nigrostriatal lesions were confirmed by immunohistochemical detection of 
tyrosine hydroxylase (TH) on free-floating sections from the striatum (anti-TH 1:1,000; 
Millipore, Temecula, USA). C-fos, FosB and DARPP-32 expression were assessed by 
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immunohistochemistry on free-floating striatal sections (anti-c-Fos 1:15,000; anti-FosB 
1:7,500; anti-DARPP-32 1:500) as previously described (Ruiz-DeDiego et al., 2015 and 
Granado et al., 2007).  
  
In vitro electrophysiology 
Experiments were conducted in brain slices prepared from the SNr of 6-month-old mice. 
These mice were sham lesioned and were injected with AAV particles, as described above 
(vector injection), 16 weeks prior to experiments. Mice were deeply anaesthetised with 
isoflurane and decapitated. Brains were quickly removed and immersed in ice-cold slicing 
solution containing 210 mM sucrose, 10 mM NaCl, 1.9 mM KCl, 1.2 mM Na2HPO4, 33 mM 
NaHCO3, 6 mM MgCl2, 1 mM CaCl2 and 10 mM glucose; pH 7.3-7.4 when bubbled with 
95% O2 and 5% CO2. The SNr was then sectioned into 300 μm coronal slices, using a 
vibrating microtome (Pelco 1000, Ted Pella, Inc). Slices were immediately placed in an 
incubation chamber filled with artificial cerebrospinal fluid (ACSF) maintained at 36°C and 
containing 125 mM NaCl, 2.5 mM KCl, 1.25 mM Na2HPO4, 10 mM glucose, 25 mM 
NaHCO3, 0.4 mM ascorbate, 1 mM MgCl2 and 2 mM CaCl2, pH 7.3-7.4 when gassed with 
95% O2 and 5% CO2. After 5 min incubation at 36°C, brain slices were stabilised at room 
temperature in the same solution for at least 30 min before they were transferred to the 
recording chamber. 
For recording, slices were transferred to a submersion chamber and superfused at 2  ml. min−1 
with oxygenated ACSF at 30-32°C. Whole-cell recordings were obtained from visually 
identified neurons in the SNr using a Nikon microscope equipped with IR-DIC optics. 
Pipettes pulled from borosilicate glass capillaries had a resistance of 4-6 MΩ when filled with 
the following solutions. Solution A (used for current clamp experiments): 120 mM potassium 
gluconate, 10 mM KCl, 10 mM HEPES, 0.2 mM EGTA, 4.5 mM MgATP, 0.3 mM NaGTP, 
14 mM sodium phosphocreatine; pH adjusted to 7.2-7.4 with KOH. Solution B (used for 
voltage clamp experiments): 130 mM CsMeSO4, 10 mM HEPES, 0.2 mM EGTA, 4.5 mM 
MgATP, 0.3 mM NaGTP, 14 mM sodium phosphocreatine, 10 mM TEA-Cl, 5 mM QX-314-
Br; pH adjusted to 7.2-7.4 with CsOH. Recordings were obtained using Multiclamp 700B 
amplifiers (Molecular Devices, San Jose, USA). Signals were low-pass filtered at 6 kHz and 
digitised at 20 kHz using DigiData 1200 acquisition interfaces (Molecular Devices). Data 
acquisition and analysis were performed using Clampex 10.2 and CampFit 10.2 software 
(Molecular Devices). In voltage-clamp mode, the pipette capacitance was compensated and 
series resistance was continuously monitored but was not compensated. Only recordings with 
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a stable series resistance of <20 MΩ were used for analysis. When current-clamp mode was 
used, series resistance and pipette capacitance were monitored and corrected using bridge and 
capacitance neutralization.  
 
Data and statistical analysis 
Data and statistical analyses comply with the recommendations on experimental design and 
analysis in pharmacology (Curtis et al., 2015). Data in figures are expressed as mean ± 
standard error of the mean (SEM). Data omission or exclusion criteria: in some cases, mis-
injection of AAV caused insufficient AAV-dependent ChR2 expression, or optic fibres were 
not placed over the SNr. These animals were excluded, resulting in slightly unbalanced 
experimental groups. Statistical analysis was performed using SigmaPlot 11.0 
( RRID:SCR_003210, Systat Software Inc, UK). The significance level was set at P < 0.05. 
Depending on the number of experimental groups and factors to be compared, statistical 
analyses were performed with t-tests or two-way or repeated measures ANOVAs followed by 
post hoc tests (Bonferroni) when appropriate. Before applying parametric tests, data were 
tested for normality with the Kolmogorov-Smirnov test and homoscedasticity with the 
Levene median test.  
 
Materials  
6-OHDA hydrobromide with added ascorbic acid, L-DOPA, benserazide hydrochloride, 
NaCl, KCl, Na2HPO4, NaHCO3, MgCl2, CaCl2, ascorbate, HEPES, EGTA, MgATP, NaGTP, 
sodium phosphocreatine, KOH, CsMeSO4, NaGTP, TEA-Cl and CsOH were purchased from 
Sigma-Aldrich (St. Louis, USA). QX-314-Br was from Tocris (Bristol, UK). AAV was 
purchased from Vector Core (North Carolina University, Chapel Hill, USA). TH antibody ( 
cat# AB152, RRID: AB_390204) was from Millipore (Burlington, USA). cFos (cat# sc-7202, 
RRID: AB_2106765)  and FosB (cat# Sc- 28213, RRID: AB_2106911)  antibodies were 
from Santa Cruz Biotechnology (Santa Cruz, USA). DARPP-32 antibody (cat# 611520, 
RRID: AB_398980) was from Becton Dickinson (Franklin Lakes, USA).   
 
Nomenclature of Targets and Ligands aterials  
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017). 
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RESULTS 
Validation of the optogenetic approach in brain slices 
To selectively stimulate striatonigral axon terminals in the SNr, we injected adeno-
associated viral (AAV) particles expressing the fusion protein ChR2-EYFP, driven by the 
CaMKIIa promoter, in the striatum of C57BL6 mice. Histology confirmed the expression of 
ChR2-EYFP in the striatum as well as in the synaptic terminal field of striatonigral neurons 
in the SNr (Figure 1A). Whole-cell patch clamp recordings of SNr neurons in coronal 
brainstem slices, 16 weeks after intrastriatal AAV-ChR2-EYFP injection, were used to 
determine if light stimulation of striatonigral terminals induces GABA-mediated inhibition of 
SNr neurons (Figure 1B). Exploratory current clamp studies showed that both continuous (1 
s) and pulsed train illumination (pulses of 5-20 ms duration at 10-20 Hz; 447 nm light 
source), at intensities of 1-10 mW, markedly inhibited the firing of SNr neurons (>90% 
inhibition of firing, 4 cells from two animals, regardless of light stimulation protocol). 
Voltage clamp studies showed that 1, 5 or 20 ms- long light pulses evoked IPSCs in SNr 
neurons, which were almost completely blocked by the non-competitive GABA-A receptor 
antagonist picrotoxin (10 cells from 5 animals; data corresponding to 20 ms pulses are shown 
in Figure 1C). Additional current clamp experiments were performed to characterize the 
effect of 20 Hz trains of light pulses, which in preliminary behavioural experiments provided 
promising results (see below). On average, it was possible to nearly completely inhibit the 
spontaneous tonic firing of SNr neurons located near the centre of the light field with 20 Hz 
trains of 5 or 20 ms duration pulses of an intensity of ~8 mW (7 cells from 5 animals; data 
obtained with 20 ms pulses are shown in Figure 1D-E). Addition of picrotoxin to the bath 
completely blocked the effect of optostimulation of striatonigral terminals on SNr firing 
(Figure 1D-E).  
These results indicate that ChR2 is efficiently expressed and functional in striatonigral 
terminals. 
 
Parkinson-like symptoms and dopamine denervation 
Parkinson- like phenotypes were tested three weeks after lesion in order to select 
animals with marked motor coordination deficits (rotarod) and a reduction of contralateral 
forelimb use (cylinder test) and vertical activity (multicage activity meter system) (Figure 
2A-C). Dopaminergic degeneration in these animals was further confirmed post-mortem by 
immunohistochemistry, assessing TH fibre loss, and determining striatal volume with a 
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complete loss of TH-immunoreactive fibres (Figure 2D-F). We also verified ChR2-YFP 
expression in DARPP32-positive striatal neurons and in DARPP32-positive fibres in the SNr 
– the projection field of dMSNs (Figure 2G).  
 
Optogenetic stimulation of striatonigral terminals induces abnormal involuntary 
movements in 6-OHDA lesioned mice 
 To examine the effect of striatonigral terminal optostimulation on dyskinetic 
behaviour, a fibre optic cannula was implanted on the ipsilateral SNr of lesioned or sham-
operated mice transduced with ChR2-EYFP; various light stimulation protocols were tested 
in sham and 6-OHDA mice. To determine the optimal intensity of light pulses, mice were 
stimulated with a continuous 15 s blue laser pulse at different intensities (1, 2, 5, 8, 10, 12 
mW). Abnormal movements resembling axial, orofacial and limb dyskinesia induced by L-
DOPA were readily detected in 6-OHDA-lesioned animals from 2 mW and progressively 
increased to reach a plateau at 10 mW (Figure 3A). We therefore used 10 mW for subsequent 
experiments. For pulsatile stimulation, we used 30 s and 10 mW pulse trains at different 
frequencies (10-20 Hz) and pulse duration (5-20 ms). No dyskinesia was observed with the 
10 Hz-5 ms protocol, however, 20 Hz-5 ms elicited weak dyskinetic symptoms (suboptimal 
protocol), which increased at 20 Hz-20 ms bursts (Figure 3B). Dyskinetic symptoms elicited 
with 20 Hz-20 ms light bursts were similar to those elicited with continuous light.  Each 
pulsatile protocol was tested in two different sessions (48 h apart); each session consisted of 
two trials, 3 min apart. The scores during intra- and inter-session repetitions of an 
illumination protocol were similar (Figure 3C). The dyskinesia induced in 6-OHDA-lesioned 
animals was predominantly of the axial type, but abnormal limb and orofacial movements 
were also observed (Figure 3D-E). Optostimulation of striatonigral terminals also induced 
contralateral rotations in 6-OHDA-lesioned mice (Figure 3E-F). In sham-lesioned mice, 
optostimulation at the SNr with continuous light or with trains of light pulses failed to induce 
abnormal movements and overall produced very subtle behavioural effects (Figure 3A, B, F). 
Overall, these data show that in animals with severe nigrostriatal terminal degeneration 
induced by 6-OHDA, but not in sham-lesioned mice, optostimulation of striatonigral 
terminals induces a wide repertoire of abnormal movements resembling LID (hence forth 
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Chronic L-DOPA administration sensitises dyskinetic responses to striatonigral 
terminal optostimulation 
Optostimulation of MSN cell bodies induces more dyskinetic movements in L-DOPA-
primed than in naïve 6-OHDA-lesioned mice (F. Hernández et al., 2017; Perez et al., 2017; 
Ryan et al., 2018) . However, it is not known whether this sensitisation depends only on 
striatal adaptations induced by L-DOPA or if it can be partly accounted for by extrastriatal 
adaptations. To determine if exposure to L-DOPA sensitises the dyskinetic response to 
optostimulation of striatonigral terminals, sham and 6-OHDA-lesioned mice were treated 
with escalating doses of L-DOPA (3, 6, 9, and 20 mg/kg i.p., each dose given for 3 
consecutive days) and tested for the effects of optostimulation when they were "off" (L-
DOPA-free for 24 h) as represented in the timeline (Figure 4A).  
During the course of L-DOPA treatment, there was a significant increase of both OID 
and LID in the 6-OHDA-lesioned animals. Stimulation (30 s, 20 Hz, 20 ms pulses, 10 mW) 
of striatonigral terminals consistently induced more dyskinesia in L-DOPA-primed than in 
naïve 6-OHDA-lesioned mice (Figure 4B). Interestingly, the dyskinesia scores during 
striatonigral terminals optostimulation were consistently higher than those induced by L-
DOPA alone at doses of 3 and 6 mg/kg. However, these differences disappeared when 
animals received higher doses of L-DOPA. The OID scores measured 24 h after 9 and 20 
mg/kg L-DOPA were comparable to those induced by L-DOPA alone (Figure 4B). Sham 
mice did not show OID at any of the conditions tested (Figure 4B). The significant increase 
of both the OID and LID scores during L-DOPA treatment indicates a progressive 
sensitisation to striatonigral terminal optostimulation.  
We also asked if OID and LID involve similar repertoires of dyskinetic movements. 
Indeed, axial dyskinesia prevailed in both conditions, especially at the beginning of 
treatment. During treatment, for both conditions, limb and orofacial dyskinesia accounted for 
~50% of the dyskinetic scores. Overall, orofacial dyskinesia seemed to be less frequent 
during OID than in LID (Figure 4C).  
To rule out any possible contribution of D1-type dopamine receptor stimulation in OID, 
light stimulation (20 Hz, 20 ms pulses, 10 mW) was applied to striatonigral axon terminals 
before and 25 min after systemic administration of the prototypical D1-type receptor 
antagonist SCH23390 (0.2 mg/kg i.p.). As expected, SCH23390 increased time of immobility 
and reduced vertical activity (Figure 5A-B). However, the D1-type receptor antagonist had no 
effect on the intensity or composition of OID (Figure 5C-D).  
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Although our optostimulation protocols were very brief (1 min of light stimulation 
during each session), the above set of animals was exposed to several illumination sessions 
before and during L-DOPA treatment. To exclude the possibility that multiple light sessions  
would generate plastic changes that could interfere with behavioural results, we prepared an 
additional set of 6-OHDA-lesioned mice (n=4) that received one illumination session before 
and one 24 h after the last escalating dose of L-DOPA (Figure 6A). In these animals, the OID 
score was also significantly higher after L-DOPA treatment. Furthermore, there was no 
difference between the OID score of the last illumination session and the LID score during 
the last L-DOPA challenge (Figure 6B-C). Importantly, there were no statistical differences 
in OID between the two sets of animals —main set of animals (figure 4) and additional set of 
animals (figure 6)— in either naïve or primed conditions. 
Finally, to completely rule out any possible non-specific effect of light stimulation in 
our results, a group of 6-OHDA-lesioned animals was injected in the striatum with an AAV 
vector carrying eYFP only and subjected to the treatments displayed in figure 6A. Light 
stimulation of striatonigral axon terminals expressing eYFP (20 Hz, 20ms, 10mW, for 30s) 
did not induce dyskinesia, neither before, nor after L-DOPA administration (Figure 6B). 
Importantly, these animals showed strong dyskinesia at 20mg/kg L-DOPA (Figure 6C).  
 
Subthreshold striatonigral terminal optostimulation enhances L-DOPA-induced 
dyskinesia, but suprathreshold stimulation does not 
The above data show that optostimulation of striatonigral terminals induces more 
dyskinesia in primed than in naïve 6-OHDA mice and that OID can be as diverse and severe 
as LID. If both treatments were recruiting the same neural substrate, additive/synergistic 
interactions would be expected at subthreshold doses of the treatments (as shown in previous 
studies ( Alcacer et al., 2017; F. Hernández et al., 2017; Perez et al., 2017). However, if one 
of the treatments were strong enough to recruit most of the substrate, it would mask the effect 
of the other treatment. Thus, we next investigated whether there were synergistic or masking 
interactions between LID and OID. 
To test if OID and LID can interact synergistically, 6-OHDA-lesioned mice (n=15) 
showing almost no dyskinesia with a weak light stimulation protocol (30 s, 20 Hz, 5 ms 
pulses, 10 mW) were treated with a subthreshold dose of L-DOPA (2 mg/kg). These mice 
were then tested again for the effect of the illumination protocol 15 min after the L-DOPA 
challenge (Figure 7A). The combined treatment produced higher dyskinesia scores than either 
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treatment alone (Figure 7B; p<0.05 for the interaction in two-way repeated measures 
ANOVA), indicating a synergistic effect.  
We speculated that if illumination recruited a large part of the striatonigral terminals, 
and LID depended mainly on the degree of dMSN activation, additional effects of L-DOPA 
on dMSN cell bodies would not further increase the dyskinesia score. Alternatively, if LID 
were promoted by pathways parallel to dMSNs, such as D2R-mediated inhibition of the 
indirect pathway, L-DOPA combined with striatonigral terminals illumination would yield a 
higher dyskinesia score than illumination alone. The same animals were therefore further 
tested for the interaction between our standard illumination protocol (30 s, 20 Hz, 20 ms- long 
pulses, 10 mW) and escalating doses of L-DOPA (3, 6, 9, and 20 mg/kg i.p.) as depicted in 
Figure 7A. 
Importantly, in L-DOPA-primed animals, striatonigral terminal illumination plus L-
DOPA did not yield a higher dyskinesia score than illumination alone in any of the conditions 
tested (Figure 7C). This cannot be attributed to a ceiling effect, since at 3 mg/kg of L-DOPA, 
the OID and LID scores were well below those at 20 mg/kg L-DOPA. Additionally, the 
subtypes of dyskinesia composing OID, LID and dyskinesia induced by combined treatment 
with light and L-DOPA were similar.  
 
Expression of dyskinesia-related molecular markers in the striatum 
Increased phosphorylation of ERK1/2 and increased expression of cFos and FosB in 
dMSNs in the denervated striatum have been directly associated with LIDs (Andersson et al., 
1999); Pavón et al., 2006); Darmopil et al., 2009) and also with dyskinesias induced by 
optogenetic stimulation of striatal cell bodies (Perez et al., 2017; F. Hernandez et al., 2017). 
We investigated if optostimulation of striatonigral terminals also induces an increase in c-Fos 
and FosB in the striatum. Nine days after the last L-DOPA administration, sham and 6-
OHDA-lesioned animals were stimulated with the same protocol (20Hz 20ms 10 mW, 2 x 
30s) and perfused 50 minutes later. We found a slight but significant increase in the 
expression of c-Fos in the ChR2 striatum of the 6-OHDA-lesion mice compared with the 
ChR2 striatum of sham mice (Figure 8A). This increase was much smaller than that expected 
for animals treated with dyskinetic doses L-DOPA and perfused 50 min after the last L-
DOPA challenge. For instance, there was a high increase of FosB expression in the 6-OHDA-
lesioned mice, which probably reflects residual expression after the last L-DOPA challenge 
performed nine days before (Figure 8B). FosB expression was observed in approximately 
1000 striatal cells/mm2, which is about 60 to 80% the density of FosB positive cells observed 
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in the striatum of 6-OHDA-lesioned mice shortly after a dyskinetogenic L-DOPA challenge  
(Pavon et al., 2006; Darmopil et al. 2009). In contrast, c-Fos was observed in about 50 striatal 
cells mm2 (Figure 8A). There were no significant differences in the contralateral striatum or 
in sham mice.  
 
DISCUSSION  
Our results reveal that selective activation of the striatonigral terminals induces 
dyskinesia in a mouse model of Parkinson’s disease, but not in control animals. Importantly, 
the repertoire of abnormal movements elicited by this optogenetic approach is similar to that 
induced by L-DOPA. Our study also shows that optical stimulation induces more severe 
dyskinetic behaviour in L-DOPA-primed mice, indicating that chronic L-DOPA 
administration sensitises the behavioral response to striatonigral terminals optostimulations. 
Nevertheless, combination of L-DOPA and optostimulation shows synergy at subthreshold 
doses of both treatments, yet, suprathreshold light stimulation interferes with the dyskinetic 
effect of higher L-DOPA doses, suggesting that both treatments act on the same neural 
substrate (Figure 9). In summary, this work supports that dyskinesia can be triggered by 
activation of direct pathway axon terminals at the SNr. 
Pioneering studies in mice have shown that optogenetic stimulation of dMSN cell 
bodies (Kravitz et al., 2010) and axon terminals (Borgkvist et al., 2015) cause an increase in 
normal motor activity and an improvement of Parkinson-like motor symptoms. Improvement 
of symptoms is linked to inhibition of SNr neurons by GABA released from striatonigral 
axon terminals (Borgkvist et al., 2015; Freeze et al., 2013), as predicted by classical basal 
ganglia models (Albin et al., 1989). It is also in line with electrophysiological evidence from 
studies that find inhibition of GPi and SNr neurons in animal models of PD and patients 
treated with L-DOPA and mixed D1/D2 agonists (e.g. apomorphine) at doses that reduce 
parkinsonian symptoms (Boraud et al., 2001; Filion et al., 1991; Lozano et al., 2000; Papa et 
al., 1999). The latter studies also show that the transition from the "on" therapeutic state to 
the dyskinetic state is related to an escalation of inhibition at the level of the GPi and SNr 
(Boraud et al., 2001; Filion et al., 1991; Lozano et al., 2000; Papa et al., 1999). Consistent 
with the view that LID is mediated by dMSN inhibition of basal ganglia output, optogenetic 
stimulation of dMSN axon terminals at the level of the SNr induces a full repertoire of 
dyskinetic movements in PD mice. These movements are as severe as those induced by a 
high dose of L-DOPA, and even mask LID when both treatments are given simultaneously. 
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Studies in 6-OHDA-lesioned rodents not previously treated with L-DOPA have shown 
that optogenetic stimulation of striatal neuron cell bodies can induce abnormal movements 
(F. Hernández et al., 2017; Perez et al., 2017; Ryan et al.2018). The striatum shows a number 
of changes after chronic nigrostriatal lesion, including an increase in dMSN somatic 
excitability (Fieblinger et al., 2014, Suárez et al., 2014, 2016, 2018). Because MSNs fire 
more spikes in PD animals than controls when depolarizing current is applied through a 
somatic recording micropipette, a comparable increase in their firing response would be 
expected if current were instead applied through somatic ChR2 channels. Therefore, changes 
in MSN somatodendritic excitability could have contributed to dyskinesia induced by 
optogenetic stimulation in previous studies. Because stimulation of ChR2 at striatonigral 
axon terminals could have produced antidromic spike invasion of dMSN cell bodies in our 
experiments, a contribution of changes in dMSN somatodendritic excitability to our results 
cannot be ruled out. On the other hand, modification of orthodromic activity by local 
plasticity at or downstream striatonigral axon terminals has very likely contributed to our 
findings. Borgkvist et al. (2015) have shown that an increased probability of GABA release 
from striatonigral terminals contributes to a sensitised motor response in 6-OHDA mice. 
Additionally, a recent study performed in PD patients suggests that inhibitory transmission in 
the SNr can suffer potentiation after repeated stimulation (Milosevic et al., 2018). Further 
examples of plasticity mechanisms induced by 6-OHDA lesion in rodents, that could have 
contributed to OID in our studies, include a reorganisation of functional movement 
representation maps in the motor cortex (Brown et al., 2004; Viaro et al., 2011) and 
accompanying structural and functional changes occurring in cortical neurons (Lindenbach & 
Bishop, 2013; Villalba et al., 2015).   
As with dyskinesia induced by optostimulation of striatal cell bodies (F. Hernández et 
al., 2017; Perez et al., 2017; Ryan et al., 2018), or chemogenetic stimulation of dMSNs 
(Alcacer et al., 2017), dyskinesia induced by stimulation of striatonigral axon terminals is 
enhanced after treating 6-OHDA animals with L-DOPA. Interestingly, many of the cellular 
and circuit adaptations occurring in PD seem to be homeostatic in nature and are partially 
reversed by L-DOPA therapy (Fieblinger et al., 2014; Suarez et al., 2016, 2018). For 
instance, L-DOPA treatment does not exacerbate, but instead partially normalizes the somatic 
excitability of MSNs in 6-OHDA mice (Fieblinger et al., 2014; Suárez et al., 2014, 2016, 
2018). Whether the excitability of striatonigral axon terminals is re-established or 
exacerbated after L-DOPA priming remains unknown, although L-DOPA administration 
 
 
This article is protected by copyright. All rights reserved. 
induces more GABA release in the SNr of L-DOPA-treated than in naïve 6-OHDA animals 
(Yamamoto et al., 2006). Further adaptations in movement representations in the motor 
cortex are seen in L-DOPA-treated 6-OHDA animals, which could also contribute to the 
abnormal response to striatonigral axon terminals stimulation in our experiments ( Viaro et 
al., 2011). 
In previous studies, dyskinesia induced by opto- and chemogenetic stimulation of 
dMSNs was less severe than LID and interacted additively with LID (Alcacer et al., 2017; 
Perez et al., 2017). These findings were interpreted as supporting that mechanisms beyond 
dMSN activation contribute to LID. For instance, Alcacer et al. (2017) found dyskinesia 
scores resembling those observed in LID when chemogenetic activation of dMSN was 
combined with a D2 agonist, suggesting that D2R inhibition of iMSN is necessary for full 
expression of LID. Furthermore, a genetic model allowing to “trap” active neurons during 
LID recruited mainly dMSN but also iMSN (Girasole et al., 2018) and recent studies show 
modulations of activity in both dMSN and iMSN during LID (Parker et al., 2018; Ryan et al., 
2018). However, optostimulation of striatonigral axon terminals can cause more powerful 
dyskinesia than moderate and even high doses of L-DOPA, which cannot be further increased 
by combining optostimulation with L-DOPA. Thus, based on our findings, it is not necessary 
to invoke mechanisms other than striatonigral inhibition of SNr neurons for full expression of 
LID. It seems likely that targeting striatonigral axon terminals rather than striatal cell bodies  
can recruit a wider population of dMSNs than in previous optogenetic studies. It is also likely 
that optogenetic stimulation of axon terminals might allow a more powerful effect on 
striatonigral outflow than chemogenetic stimulation of dMSNs. Finally, targeting striatonigral 
axon terminals could provide a more certain means of selectively activating dMSNs, because 
even when D1R promoters are used to drive the expression of opto/chemogenetic transgenes 
in striatal neurons, striatal illumination and systemic administration of CNO could affect 
D1R-expressing striatal neurons other than dMSNs and targets of dMSNs other than the SNr.   
Regarding the expression of dyskinesia-related molecular markers, our results show 
that c-Fos expression is slightly yet significantly higher only in the 6-OHDA-lesioned 
hemisphere after ChR2 activation in the ipsilateral striatonigral terminals. This result is likely 
linked to the dyskinetic activity displayed by the animals just 50 minutes before perfusion. 
FosB expression was also significantly higher in the 6-OHDA lesioned hemisphere, but 
probably as a consequence of the chronic L-DOPA treatment stopped nine days before 
perfusion (Andersson et al., 1999; Pavon et al., 2006). Interestingly, this residual population 
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of FosB positive cells was much higher than the population of cells expressing c-Fos, 
suggesting that the full dyskinetic state induced by optostimulation of striatonigral terminals 
produces very limited transcriptional activity in the striatum. In contrast, dyskinesia induced 
by light stimulation of striatal cell bodies was accompanied by a marked increase in the 
expression of dyskinesia-related molecular markers (Perez et al., 2017; Hernandez et al., 
2017). Whether the observed increase of c-Fos relates to antidromic activity in dMSN or to 
the dyskinetic motor activity induced before perfusion remains to be determined. Importantly, 
sham animals, which showed only a slight increase in motor activity during light stimulation, 
did not show higher c-Fos expression in the ChR2 hemisphere. Together with previous 
studies showing limited effects of backpropagating action potentials in dMSN dendrites (Day 
et al., 2008), and studies showing plasticity at inhibitory synapses in the SNr both in animal 
PD models and patients (Yamamoto et al., 2006; Borgkvist et al., 2015; Milosevic et al., 
2018), the data favour the view that local plasticity at striatonigral synapses play a role in our 
findings. 
In conclusion, we show that optostimulation of striatonigral axons can produce a full 
dyskinetic state in chronically and severely DA-depleted animals that cannot be further 
modulated by simultaneous administration of L-DOPA. This introduces the striatonigral 
synapse as a particularly attractive target for future strategies aimed at improving or 
managing LID in patients.  
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Figure 1. Illumination of ChR2-transfected striatonigral terminals inhibits SNr 
neurons. A. Coronal sections of dorsal striatum (left) and the SNr (right) showing a 
representative injection site and ChR2-eYFP expression at striatonigral terminals, 
respectively. Note the track left by the fibre optic cannula in the SNr section. B. Schematic of 
the approach to ex vivo whole cell recording and illumination. C. Representative trace of an 
IPSC recorded at a holding potential of 0 mV in a SNr neuron, evoked by a 20 ms light pulse, 
before and after adding picrotoxin (50 uM) to the bath (left), and population data 
corresponding to ten SNr neurons recorded from five animals (right, * p<0.05, paired t test). 
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D. Representative current clamp recording of a SNr neuron inhibited during light stimulation 
of striatonigral terminals. E. Effect of trains of light pulses (20 ms, 20 Hz, ~8 mW) on the 
tonic firing of SNr neurons, before and after adding picrotoxin (50 uM) to the bath. Left: time 
course of effects. Bin size: 100 ms. Right: Data were integrated along the laser off and laser 
on periods and subjected to statistical analysis. 7 cells from 5 animals. *p<0.05, Bonferroni 
posthoc test after significant two way ANOVA interaction. Data are mean ± SEM. cc: corpus 
callosum; SNl: substantia nigra pars lateralis; SNc: substantia nigra pars compacta; SNr: 
substantia nigra pars reticulata; St: striatum 
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Figure 2. Efficacy of dopamine lesions and channelrhodopsin viral infection. A-C. 6-
OHDA-lesioned animals showed motor coordination deficits (A; * p<0.05, main effect of 
treatment, two way repeated measures ANOVA), reduced contralateral forelimb use (B; t-
test, * p<0.05) and reduced vertical activity (C; Mann-Whitney test * p<0.05). D. 
Representative photomicrographs of striatal sections illustrating the loss of TH-positive fibres 
in 6-OHDA lesioned mice. E-F. The efficacy of 6-OHDA lesions was assessed by 
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quantifying the percentage of striatal volume that was completely denervated (E; Mann-
Whitney test, * p<0.05) and striatal TH-positive fibre depletion (F; Mann-Whitney test * 
p<0.05). G. Representative low-magnification confocal images obtained from the striatum 
and SNr illustrating ChR2-EYFP expression in DARPP-32 neurons (striatum) and fibres 
(SNr) in AAV-ChR2 infected mice. Right-most panels show magnifications of the merge 
panels. Scale bars: 500m, 50 m. STR: striatum; SNr: substantia nigra reticulata., Sham n= 
6; 6-OHDA n=8. Data are mean ± SEM for A and B, median and individual data points for C, 
E and F.  
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Figure 3. Optostimulation of striatonigral terminals induces dyskinesia in 6-OHDA 
mice. Total dyskinesia (axial+forelimb+orofacial) score after continuous (A) or pulsatile (B) 
illumination of striatonigral terminals in 6-OHDA-lesioned mice. Note that illumination in 
sham-lesioned mice does not induce dyskinesia. C. Total dyskinesia score during striatonigral 
terminal stimulation showed inter-session and intra-session stability, two way repeated 
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measures ANOVA, inter-session main effect not significant, intra-session main effect not 
significant and interaction not significant. D. Types of dyskinesia observed during SNr 
illumination in 6-OHDA-lesioned mice. E. Photographs of 6-OHDA-lesioned mouse with 
laser OFF and laser ON. Optostimulation of striatonigral terminals induced dyskinesia. F. 
Rotational locomotive behaviour induced by the 20 Hz-20 ms protocol of optostimulation of 
striatonigral axon terminals in sham- and 6-OHDA-lesioned mice. * p<0.05, Bonferroni post 
hoc after two-way repeated measures ANOVA with significant interaction. Data are mean ± 
SEM. Sham n=6, 6-OHDA n=8. 
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Figure 4. Optostimulation of striatonigral terminals induces greater dyskinesia in 
primed than in naïve 6-OHDA mice. A. Experimental timeline highlighting in black the 
behavioural manipulation rated in B-C. B. Total dyskinesia score induced by 3 consecutive 
daily doses of L-DOPA (LID) or by optostimulation (OID) 24 h after the third day of each 
escalating dose of L-DOPA treatment. *p<0.05 OID vs LID; $ p<0.05 OID at 20 mg/kg vs 
OID at naïve and OID after 3 mg/kg L-DOPA; # p<0.05 LID at 9 or 20 mg/kg vs LID at 3 
and 6 mg/kg L-DOPA; Bonferroni post hoc comparisons after significant interaction in a 
repeated measures two-way ANOVA. C. Type and intensity of dyskinesia induced by three 
days of each escalating dose of L-DOPA (LID) or by optostimulation (OID) applied 24 h 
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Figure 5: The D1-type dopamine receptor antagonist SCH23390 does not modify 
optostimulation-induced dyskinesia. A and B. SCH23390 (0.25 mg/kg, i.p.) increases 
immobility (A; * p<0.05, paired t test) and reduces vertical activity (B; * p<0.05, paired t 
test) in 6-OHDA-lesioned mice. C. Total dyskinesia score (axial, orofacial, limb) induced by 
optostimulation of striatonigral terminals in 6-OHDA-lesioned mice, before and after 
administration of the D1-type receptor antagonist SCH23390 (0.25 mg/kg, i.p.). No 
significant difference was found (paired t test not significant) D. Composition of OID before 
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Figure 6. Optostimulation in an independent set of animals confirms the L-DOPA 
priming effect on OIDs A. Experimental timeline highlighting in black the behavioural 
manipulation rated in B-C. B. OID observed in 6-OHDA-lesioned animals expressing ChR2-
eYFP in striatonigral terminals (n=7) before and after chronic L-DOPA treatment (*p<0.05, 
paired t-test), and in an additional group of 6-OHDA-lesioned mice expressing eYFP only 
(n=7). C. Composition of total dyskinesia scores for OID after the chronic L-DOPA 
treatment shown in A, and for LID induced by 20 mg/kg L-DOPA in the same animals. Total 
AIM scores did not significantly differ between these conditions ( paired t test not 
significant). Data are mean ± SEM 
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Figure 7.  Optical stimulation potentiates the effect of L-DOPA on dyskinesia. A. 
Experimental timeline highlighting in black the behavioural manipulations rated in B and C. 
B. Interaction between subthreshold illumination of striatonigral terminals (20 Hz-5 ms, 10 
mW) and a low dose of L-DOPA (2 mg/kg) (n=14); * p<0.05, Bonferroni post hoc 
comparison after significant interaction in repeated measures two-way ANOVA. C. 
Interaction between suprathreshold illumination of striatonigral terminals (20 Hz-20 ms, 10 
mW) and increasing doses of L-DOPA (3 to 20 mg/kg). Two-way ANOVA interactions 
reached significance at 3 (n=8), 6 (n=8), 9 (n=8) and 20 (n=12) mg/kg L-DOPA. Light 
stimulation plus L-DOPA did not differ from light stimulation alone at any of the conditions 
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Figure 8. Optostimulation of striatonigral axon terminals in the SNr induced subtle 
cFos expression in the striatum in 6-OHDA-lesioned animals. A. Left. High-power 
photomicrographs of sham- and 6-OHDA-lesioned mice, representing contralateral and 
ipsilateral (ChR2) striata immunostaining for cFos. Right. Locations of sampled areas are 
indicated by black boxes in the modified section from the Paxinos and Franklin (2001) brain 
atlas at 0.65 mm anterior to bregma. Histograms represent the quantification of cFos-
immunoreactive nuclei. Note the higher expression in the ipsilateral striatum of 6-OHDA-
lesioned mice. B. Left. High-power photomicrographs of sham- and 6-OHDA-lesioned mice 
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showing contralateral and ChR2 striatal immunostaining for FosB. Right. Sample locations 
as seen in A. Histograms represent FosB quantification. Also note the higher expression in 
ChR2 striatum. Data (mean ± SEM) were analysed by two-way ANOVA followed by 
posthoc test after significant interactions. * p<0.05 vs. sham ChR2; # p<0.05 vs. 6-OHDA 
contralateral. Scale bars: 200 μm and 50 μm.  
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Figure 9. Proposed mechanisms of the interacting effects of optostimulation and L-
DOPA. Without stimulation, the SNr neurons fire action potentials tonically ("baseline"). 
When L-DOPA and light are delivered at low doses, their effects add to each other 
("synergistic effect"). This could be explained by actions of both treatments on the same 
pathway (as illustrated) or on parallel pathways converging onto SNr neurons. In contrast, 
suprathreshold light stimulation masked the effect of even high doses of L-DOPA ("masking 
effect"), suggesting that stimulation of striatonigral axon terminals "clamps" basal ganglia 
output making it insensitive to actions of L-DOPA on the same or additional pathways. 
Circles in grayscale give out a population perspective of SNr neuronal activity.  
 
 
